Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Turning Vaccine Priority Upside Down: Applying H1N1 Lessons To COVID-19

Executive Summary

A successful COVID-19 vaccine candidate will create a critical challenge: who receives the first doses of what is bound to be a constrained supply? Vaccine developers see useful lessons from the 2009 H1N1 outbreak – but a very different priority order.

You may also be interested in...

Vaccines After COVID: Catch-Up Watch Under Way

There has been a dramatic drop-off in routine immunization rates in the US and around the world amid the COVID-19 outbreak. The catch-up effort may complicate the pandemic response efforts.

Manufacturing Pace Is Key For COVID-19 Vaccine Candidates Hoping To Jump To ‘Warp Speed’

Ease of manufacturing scale up may determine which candidates advance furthest in the US government's partnership with industry to speed COVID-19 vaccines to patients. Senior government officials also discussed approval standards, how a vaccine would be distributed, and how much the government and Americans could pay in a 16 June press call.

Moderna’s Early Data On COVID-19 Vaccine Prompts Dosing Revisions For Phase II

Move to lower doses could ease manufacturing scale-up burden a bit; first eight volunteers produced antibodies which match or surpass those seen in patients who have recovered from COVID-19 – but big test awaits in Phase III.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts